^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    sildenafil

    i
    Other names: UK 92480
    Company:
    Generic mfg.
    Drug class:
    PDE5 inhibitor
    Related drugs:
    12d
    Phosphodiesterase 5 Inhibitor Sildenafil Inhibits HPV+ Cervical Cancer Cells and Cervical Cancer Stem Cells by Apoptotic Induction and Telomerase Activity Modulation. (PubMed, Anticancer Res)
    The PDE5 inhibitor sildenafil might be repurposed to be a possible therapeutic option for treating cervical cancer. Its efficacy extends to both HPV-positivity and CSCs, addressing a significant portion of cervical cancer cases.
    Journal
    |
    SOX2 • POU5F1 (POU Class 5 Homeobox 1) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1)
    |
    POU5F1 expression
    |
    sildenafil
    28d
    Asciminib With or Without Sildenafil for Brain Tumors (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Washington University School of Medicine | Trial completion date: Aug 2027 --> Nov 2027 | Trial primary completion date: Jul 2027 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Scemblix (asciminib) • sildenafil
    1m
    844700336/0156/1: Multicenter study on patients ability to independently and safely use of Sildenafil 100 mg for erectile dysfunction. (2025-522923-81-00)
    P4, N=200, Recruiting, ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    sildenafil
    2ms
    Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer (clinicaltrials.gov)
    P3, N=188, Not yet recruiting, University Hospital, Rouen | Trial completion date: May 2028 --> Feb 2030 | Trial primary completion date: May 2028 --> Feb 2030
    Trial completion date • Trial primary completion date
    |
    sildenafil
    2ms
    SHINE1: Sildenafil Plus Hypothermia to Treat Neonatal Encephalopathy (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Assistance Publique - Hôpitaux de Paris | Trial completion date: Jan 2028 --> May 2029 | Trial primary completion date: Feb 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    sildenafil
    2ms
    MoD: Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension (clinicaltrials.gov)
    P3, N=28, Completed, Johns Hopkins University | Active, not recruiting --> Completed | N=100 --> 28 | Trial completion date: May 2026 --> Dec 2025 | Trial primary completion date: May 2026 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    sildenafil
    2ms
    22598: A study to learn how safe nurandociguat is when taken with sildenafil in men with arterial hypertension. (2025-522336-14-00)
    P1, N=36, Not yet recruiting, Bayer AG
    New P1 trial
    |
    sildenafil
    2ms
    844700336/0156/1: Multicenter study on patients ability to independently and safely use of Sildenafil 100 mg for erectile dysfunction. (2025-522923-81-00)
    P4, N=200, Not yet recruiting, ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
    New P4 trial
    |
    sildenafil
    2ms
    Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients (clinicaltrials.gov)
    P4, N=500, Recruiting, Mansoura University
    New P4 trial
    |
    sildenafil
    2ms
    Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD (clinicaltrials.gov)
    P2, N=160, Recruiting, University of Alberta | Trial completion date: Dec 2025 --> May 2027 | Trial primary completion date: Dec 2025 --> May 2027
    Trial completion date • Trial primary completion date
    |
    sildenafil
    3ms
    IMPROVE-FALD: IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease (clinicaltrials.gov)
    P1, N=15, Recruiting, Children's Mercy Hospital Kansas City | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    sildenafil
    3ms
    Anti-Inflammatory and Anti-apoptotic Effects of Phosphodiesterase Inhibitors Against Streptozocin-induced Diabetic Nephropathy. (PubMed, In Vivo)
    The tested PDEIs, pentoxifylline, sildenafil, and milrinone, exhibit significant anti-inflammatory and anti-apoptotic effects, highlighting their potential in slowing the progression of diabetic nephropathy.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein)
    |
    Zanosar (streptozocin) • sildenafil